Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | KNSA |
---|---|---|
09:32 ET | 3891 | 19.9 |
09:38 ET | 156 | 19.6505 |
09:39 ET | 100 | 19.715 |
09:43 ET | 200 | 19.76 |
09:45 ET | 600 | 19.69 |
09:48 ET | 100 | 19.7 |
09:52 ET | 100 | 19.7 |
09:56 ET | 300 | 19.71 |
09:57 ET | 100 | 19.68 |
09:59 ET | 550 | 19.715 |
10:01 ET | 943 | 19.66 |
10:06 ET | 700 | 19.7 |
10:08 ET | 600 | 19.7 |
10:10 ET | 503 | 19.61 |
10:12 ET | 892 | 19.56 |
10:21 ET | 100 | 19.6 |
10:24 ET | 300 | 19.61 |
10:32 ET | 400 | 19.61 |
10:33 ET | 402 | 19.635 |
10:37 ET | 700 | 19.69 |
10:39 ET | 1100 | 19.63 |
10:46 ET | 1695 | 19.475 |
10:48 ET | 200 | 19.48 |
10:50 ET | 300 | 19.5 |
10:51 ET | 100 | 19.515 |
11:00 ET | 100 | 19.57 |
11:02 ET | 100 | 19.56 |
11:06 ET | 1500 | 19.54 |
11:09 ET | 1007 | 19.58 |
11:13 ET | 400 | 19.525 |
11:15 ET | 200 | 19.58 |
11:18 ET | 300 | 19.595 |
11:20 ET | 100 | 19.61 |
11:22 ET | 100 | 19.57 |
11:24 ET | 600 | 19.525 |
11:26 ET | 400 | 19.51 |
11:29 ET | 100 | 19.47 |
11:36 ET | 400 | 19.48 |
11:38 ET | 100 | 19.495 |
11:40 ET | 1100 | 19.545 |
11:49 ET | 180 | 19.535 |
11:51 ET | 200 | 19.58 |
11:56 ET | 204 | 19.57 |
11:58 ET | 100 | 19.6 |
12:00 ET | 685 | 19.65 |
12:02 ET | 400 | 19.66 |
12:03 ET | 916 | 19.705 |
12:05 ET | 300 | 19.7 |
12:12 ET | 200 | 19.64 |
12:18 ET | 100 | 19.64 |
12:27 ET | 100 | 19.66 |
12:32 ET | 400 | 19.66 |
12:38 ET | 400 | 19.605 |
12:50 ET | 300 | 19.61 |
12:52 ET | 100 | 19.59 |
12:59 ET | 103 | 19.65 |
01:01 ET | 200 | 19.66 |
01:03 ET | 100 | 19.66 |
01:08 ET | 100 | 19.7 |
01:12 ET | 218 | 19.65 |
01:19 ET | 1500 | 19.63 |
01:26 ET | 100 | 19.64 |
01:28 ET | 825 | 19.6358 |
01:30 ET | 100 | 19.64 |
01:37 ET | 1203 | 19.655 |
01:42 ET | 621 | 19.61 |
01:44 ET | 300 | 19.59 |
01:50 ET | 100 | 19.59 |
01:53 ET | 100 | 19.605 |
01:55 ET | 400 | 19.615 |
02:00 ET | 437 | 19.63 |
02:02 ET | 803 | 19.6 |
02:04 ET | 100 | 19.62 |
02:08 ET | 100 | 19.62 |
02:13 ET | 1803 | 19.65 |
02:15 ET | 600 | 19.635 |
02:20 ET | 200 | 19.65 |
02:22 ET | 200 | 19.635 |
02:29 ET | 100 | 19.635 |
02:31 ET | 600 | 19.57 |
02:40 ET | 100 | 19.6 |
02:42 ET | 600 | 19.55 |
02:44 ET | 700 | 19.565 |
02:47 ET | 900 | 19.55 |
02:49 ET | 400 | 19.57 |
02:54 ET | 650 | 19.54 |
02:58 ET | 200 | 19.537 |
03:02 ET | 100 | 19.525 |
03:07 ET | 100 | 19.525 |
03:12 ET | 100 | 19.525 |
03:14 ET | 759 | 19.54 |
03:16 ET | 734 | 19.54 |
03:20 ET | 1006 | 19.53 |
03:21 ET | 300 | 19.505 |
03:25 ET | 300 | 19.495 |
03:27 ET | 1056 | 19.49 |
03:30 ET | 301 | 19.51 |
03:32 ET | 811 | 19.52 |
03:34 ET | 200 | 19.5 |
03:36 ET | 800 | 19.5 |
03:38 ET | 100 | 19.5 |
03:39 ET | 600 | 19.51 |
03:41 ET | 1094 | 19.56 |
03:43 ET | 1139 | 19.55 |
03:45 ET | 704 | 19.57 |
03:48 ET | 1763 | 19.56 |
03:50 ET | 1700 | 19.55 |
03:52 ET | 919 | 19.59 |
03:54 ET | 2282 | 19.59 |
03:56 ET | 2216 | 19.59 |
03:57 ET | 5894 | 19.59 |
03:59 ET | 7368 | 19.58 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Kiniksa Pharmaceuticals Ltd | 1.4B | 229.8x | --- |
Dynavax Technologies Corp | 1.4B | 220.8x | --- |
Ginkgo Bioworks Holdings Inc | 1.7B | -1.8x | --- |
MiMedx Group Inc | 1.1B | 21.0x | --- |
Xencor Inc | 1.4B | -9.7x | --- |
MannKind Corp | 1.2B | 188.2x | --- |
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.4B |
---|---|
Revenue (TTM) | $301.8M |
Shares Outstanding | 70.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.33 |
EPS | $0.09 |
Book Value | $6.23 |
P/E Ratio | 229.8x |
Price/Sales (TTM) | 4.6 |
Price/Cash Flow (TTM) | 127.6x |
Operating Margin | -10.12% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.